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Abstract
During the past 2 decades, the diagnostic and thera-
peutic approach to deep vein thrombosis (DVT) has 
greatly evolved. First, the assessment of the clinical 
probability has gained wide acceptance. Second, novel 
noninvasive diagnostic tools such as venous compres-
sion ultrasonography and D-dimer measurement have 
become available, drastically reducing the need for in-
vasive tools such as phlebography. Third, new antico-
agulant drugs, in particular low-molecular-weight 
heparins (LMWHs), have become available and have 
made DVT treatment a lot easier by allowing out-of-
hospital management.
Several diagnostic algorithms, based on the as-
sessment of clinical probability, D-dimer measurement 
and venous compression ultrasonography, have shown 
to be safe in management studies. In addition to im-
provements in diagnostic algorithms and anticoagu-
lant treatment, compression therapy by elastic stock-
ings to diminish the prevalence of the postthrombotic 
syndrome has been validated in prospective studies.
The dilemma of the need or no need for looking 
for and treating isolated calf DVT with anticoagulants 
remains a controversial issue, as do the optimal length 
and intensity of anticoagulation. In the near future, 
the emergence of several new, totally synthetic, orally 
active anticoagulant compounds, such as direct 
thrombin or factor Xa inhibitors that are presently be-
ing tested in clinical studies, could profoundly change 
the therapeutic approach to DVT.
Tiefe Venenthrombose: Risikofaktoren und Management
 Zusammenfassung
In den letzten 2 Jahrzehnten haben Diagnostik und 
Therapie der tiefen Venenthrombose (TVT) entschei-
dende Veränderungen erfahren. Erstens hat die Beur-
teilung der klinischen Wahrscheinlichkeit eine breite 
Akzeptanz gefunden. Zweitens haben sich nichtinva-
sive Abklärungsmethoden wie Kompressionsechogra-
phie und Bestimmung der D-Dimere durchgesetzt, 
was die Notwendigkeit einer invasiven Abklärung mit-
tels Phlebographie drastisch reduziert hat. Drittens 
finden neue Formen der Antikoagulation, im Speziellen 
die niedermolekularen Heparine, breite Anwendung 
und erleichtern die Behandlung einer TVT, die zurzeit 
meist ambulant durchgeführt werden kann.
Zahlreiche diagnostische Algorithmen basieren 
auf klinischer Wahrscheinlichkeit, Bestimmung der 
D-Dimere und Kompressionsechographie und haben 
sich in Studien als sicher erwiesen. Neben dem Fort-
schritt der diagnostischen Algorithmen und der Anti-
koagulation konnten prospektive Studien die Wich-
tigkeit der Kompressionstherapie mittels elastischer 
Binden zeigen und eine Verminderung der Prävalenz 
des postthrombotischen Syndroms bestätigen.
Die Diskussion über die Notwendigkeit einer Ab-
klärung und Behandlung der TVT des Unterschenkels 
bleibt kontrovers, ebenso die optimale Dauer und In-
tensität der Antikoagulation. In absehbarer Zukunft 
könnten einige neue, völlig synthetische, oral aktive 
Antikoagulanzien, wie direkte Antithrombine oder 
Anti-Faktor Xa, welche kürzlich in klinischen Studien 
getestet wurden, die therapeutischen Ansätze bei der 
TVT grundsätzlich verändern.
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Introduction
Venous thromboembolism (VTE) and its manifes-
tations, including deep vein thrombosis (DVT) 
and pulmonary embolism (PE), pose a life-threaten-
ing health problem for thousands of people each 
year. Overall, incidence of deep vein thrombosis is 
1–2/1,000 persons/year. However, incidence raises 
exponentially from less than 5 cases/100,000 persons 
< 15 years of age to 500–1,000 cases/100,000 persons 
aged 80 years [1]. Approximately one third of pa-
tients with VTE manifest PE, whereas two thirds 
manifest DVT alone. Symptoms of DVT include 
swelling of the affected limb, tenderness, erythema, 
and pain, whereas PE presents as sudden breathless-
ness with or without chest pain, or, less frequently, 
collapse with hemodynamic shock.
During the past 2 decades, the diagnostic and 
therapeutic approach to DVT has changed in several 
major ways. First, novel noninvasive diagnostic tools 
such as venous compression ultrasonography (CUS) 
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and D-dimer (DD) measurement have become avail-
able, drastically reducing the need for invasive tools 
such as phlebography [2]. Second, new anticoagulant 
treatment, in particular low-molecular-weight hepa-
rins (LMWHs), have become available and have ren-
dered the treatment of DVT easier by allowing 
out-of-hospital treatment. Third, the index of clinical 
suspicion has progressively become lower, resulting 
in the fact that the vast majority (80% or even more) 
of patients with suspected VTE do not have the dis-
ease. Fourth, noninvasive strategies have been vali-
dated in large-scale outcome studies, and more atten-
tion has been paid to their cost implications [3].
Risk Factors for Venous Thromboembolism
To improve survival, avoid recurrences, prevent com-
plications and reduce health-care costs, the occurrence 
of VTE must be reduced. To reduce VTE incidence, 
persons at risk for VTE must first be identified [4], in 
order to target prevention. Risk factors for VTE include 
increasing age, surgery, trauma, hospital or nursing-
home confinement, active neoplasia with or without 
concurrent chemotherapy, central vein catheterization 
or transvenous pacemaker, prior superficial vein throm-
bosis, varicose veins, and neurologic disease with ex-
tremity paresis; patients with chronic liver disease have 
a reduced risk [5]. Hospitalization and nursing-home 
residence together account for almost 60% of incident 
VTE events in the community. Thus, hospital confine-
ment provides an important opportunity to significantly 
reduce VTE incidence [6]. Of note, hospitalization for 
medical illness and hospitalization for general surgery 
account for almost equal proportions of VTE, empha-
sizing the need to provide prophylaxis to both of these 
risk groups. A recent epidemiologic study suggested 
that active cancer may account for almost 20% of inci-
dent VTE events occurring in the community [4]. The 
risk appeared to be higher for patients with pancreatic 
cancer, lymphoma, malignant brain tumors, cancer of 
the liver, leukemia, and colorectal and other digestive 
cancers. Cancer patients receiving immunosuppressive 
or cytotoxic chemotherapy are even at higher risk for 
VTE [7]. Central venous catheter or transvenous pace-
maker are well known risk factors for upper-limb DVT. 
However, systematic prophylaxis in these situations is 
not widely accepted [8, 9].
Among women, additional risk factors for VTE 
include oral contraceptive use and hormone therapy, 
pregnancy and the postpartum period, and therapy 
with selective estrogen receptor modulators, such as 
raloxifene. First- and third-generation oral contra-
ceptives convey higher risk than second-generation 
oral contraceptives. Other conditions associated with 
VTE include heparin-induced thrombocytopenia, 
myeloproliferative disorders, nephrotic syndrome, 
paroxysmal nocturnal hemoglobinuria, thromboan-
giitis obliterans (Buerger’s disease), thrombotic 
thrombocytopenic purpura, Behçet’s syndrome, sys-
temic lupus erythematosus, inflammatory bowel dis-
ease, homocystinuria, and possibly, hyperhomocys-
teinemia. Recently, acute infections of the urinary or 
respiratory tract in the community setting have also 
been related with a transient and modest increase in 
the risk of VTE [10].
Thrombophilias are inherited or acquired abnor-
malities associated with an increased risk of venous 
thromboembolic disease. Before 1993, a heritable 
cause of thrombophilia was detectable in a relatively 
small proportion of patients presenting with DVT or 
PE. Such abnormalities were confined to rare de-
ficiencies like antithrombin, protein C or protein S. 
The recent discovery of other two other prothrom-
botic mutations (the factor V Arg506Gln, or factor V 
Leiden mutation and the prothrombin G20210A mu-
tation), quite prevalent (about 5% up to 30% in some 
part of Sweden) in Caucasians, has highlighted a ge-
netic-mediated basis of VTE [11, 12].
Diagnosis of Deep Vein Thrombosis
Clinical Probability Assessment
Sensitivity and specificity of clinical symptoms and 
signs in suspected DVT are low when considered sin-
gly. Nevertheless, clinicians can combine these find-
ings effectively along with elements of personal and 
family history either implicitly (empirically) or by 
prediction rules or scores in order to classify patients 
according to their probability of having the disease, 
the so-called prior clinical probability [13].
In the setting of suspected DVT, the Wells’ score 
[14] has gained relatively wide acceptance in spite of 
its partial subjectivity (Table 1). It is probably not 
more accurate than the simple implicit evaluation 
[13]. However, it is easier to teach to junior physicians 
and allows discussing occasional disagreements 
among experienced clinicians on explicit grounds. 
Nevertheless, both the implicit assessment and the 
explicit Wells’ score allow usefully categorizing pa-
tients in low, intermediate, or high clinical probability 
groups in which the prevalence of DVT is approxi-
mately 5%, 20%, and 80%, respectively [15]. Most 
patients with suspected DVT have a low or interme-
diate clinical probability of having the disease. These 
patients can usually be investigated by entirely nonin-
vasive algorithms, which is an important advantage 
resulting from the evaluation of clinical probability.
DD Measurement
DD is a degradation product of cross-linked fibrin 
and its level increases in plasma of patients with acute 
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VTE. DD, when assayed by a quantitative enzyme-
linked immunosorbent assay (ELISA) or by some 
automated turbidimetric assays, has been shown 
highly sensitive (> 98%) in acute DVT, usually at a 
cutoff value of 500 µg/l [16]. Hence, a DD level below 
this value reasonably rules out acute DVT, at least in 
patients with a low or intermediate prior clinical 
probability [16]. Table 2 summarizes the pooled anal-
ysis of the published literature on most commercially 
available rapid DD tests. Tests vary with respect to 
several characteristics, including assay technique 
(ELISA, latex, or automated turbidimetric tests), 
specificity of monoclonal antibodies used, calibra-
tors, and quantitative or semiquantitative results.
In summary, highly sensitive DD assays allow ex-
clusion of DVT in outpatients with a low or intermedi-
ate clinical probability, while whole-blood agglutina-
tion tests only rule out the disease in patients with a 
low clinical probability [17]. Finally, DD is unlikely to 
be useful in very elderly patients or in hospitalized pa-
tients with suspected VTE [18] because of diminishing 
specificity of the measurement with increasing age.
Venous CUS
In studies using phlebography as gold standard, low-
er-limb venous CUS, an entirely noninvasive test, has 
a sensitivity of 97% (95% confidence interval [CI]: 
96–98%) and a specificity of 98% for symptomatic 
proximal DVT [2]. It has become the cornerstone of 
DVT diagnosis in clinically suspected individuals [19, 
20]. The single well-validated diagnostic criterion for 
DVT on CUS is absence of full compressibility of the 
deep vein when applying pressure through the ultra-
sound probe. Intraluminal venous ultrasonography 
has been reported to have variable accuracy, and nei-
ther changes in venous diameter during Valsalva ma-
neuver nor assessment of Doppler flow have been 
found to improve diagnostic accuracy for DVT [2].
Proximal Versus Proximal and Distal CUS
The observation of a very low 3-month thromboem-
bolic risk in patients with a negative CUS of the proxi-
mal veins and with clinically suspected DVT (around 
1% in management studies [13, 21–24]) questions the 
need for diagnosing so-called calf (or distal, infrapop-
liteal) DVT, at least in non-high clinical probability 
patients. Indeed, in such patients, detecting clots in 
the posterior tibial or peroneal veins or even in calf 
muscle veins may be double-edged: on the one hand, 
the potential of reducing the 3-month thromboem-
bolic risk is limited (because it is already quite low), 
and, on the other hand, the risk of false-positive find-
ings and subsequent unnecessary anticoagulant treat-
ment in patients who could be left untreated, is quite 
high. Nevertheless, recent large series suggest that 
complete examination of the leg deep vein system 
without any other exam is safe and effective in man-
aging patients with clinically suspected DVT [25–27]. 
For example, Elias et al. examined 623 patients of 
whom 401 (64.4%) were declared without DVT and 
were followed up for 3 months with a low thrombo-
embolic risk of 0.5% (95% CI: 0.1–1.8%). However, 
among the 204 patients with DVT, 92 (45%) were dis-
tal and most of them would not have been treated 
(and submitted to the hazards of anticoagulant treat-
ment) with a similarly low 3-month thromboembolic 
Items Points
Cancer + 1
Paralysis or recent immobilization + 1
Bedridden > 3 days, or surgery/trauma < 4 weeks + 1
Pain on palpation of the deep veins + 1
Edema of thigh and calf + 1 
Pitting edema (symptomatic side only) + 1
Dilated superficial veins (symptomatic side only) + 1
Alternative diagnosis at least as likely as DVT – 2
Clinical probability
Low ≤ 0
Intermediate 1–2
High ≥ 3
Table 1. The Wells’ 
score for assess-
ment of prior 
clinical probabili-
ty of deep vein 
thrombosis 
(DVT).
Tabelle 1. Kli-
nische Wahr-
scheinlichkeit ei-
ner tiefen Ve-
nenthrombose 
(DVT): 
Wells-Score.
Table 2. Performances of various D-dimer (DD) assays for diagnosing venous 
thromboembolism (VTE). Results are almost identical for suspected deep vein 
thrombosis and for suspected pulmonary embolism. CI: confidence interval.
Tabelle 2. D-Dimer-(DD-)Bestimmung für die Diagnose der venösen Thromboem-
bolie (VTE). Die Resultate für den Verdacht auf tiefe Venenthrombose und Lun-
genembolie sind annähernd identisch. CI: Konfidenzintervall.
Test (producer) n (nVTE) Sensitivity Specificity
  [% (95% CI)] [% (95% CI)]
ELISA tests
VIDAS DD (bioMérieux)a 3,575 (809) 99 (98–100) 44 (42–45)
Instant IAb (Stago) 1,549 (686) 92 (89–94) 54 (50–58)
Nycocardb (Nycomed)    938 (337) 92 (89–95) 45 (41–49)
Latexb or automated turbidimetric tests
SimpliREDb (Agen)a 2,303 (567) 85 (82–88) 69 (66–71)
Liatest (Stago) 1,113 (370) 95 (92–97) 39 (36–43)
MDA (Organon Tecnika)    642 (133) 96 (91–99) 46 (41–51)
Minutexb (Biopool)    565 (264) 89 (84–93) 58 (52–64)
DDPlus (Dade Behring)    481 (154) 96 (91–99) 46 (40–51)
Tinaquant (Boehringer Mannheim)a    286 (162) 99 (96–100) 40 (31–49)
Turbiquant (Dade Behring)    183   (19) 89 (67–99) 57 (49–64)
LPIA D-Dimer (Mitsubishi)      87   (42) 95 (89–100) 69 (55–84)
Nephelotex (Biopool)      87   (42) 98 (93–100) 65 (62–89)
a outcome studies available
b semiquantitative test
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risk if only a proximal CUS had been performed [25]. 
Schellong et al. reported a similar 3-month thrombo-
embolic risk of 0.3% in a series of 1,646 patients of 
whom 275 were positive for DVT but, again, 154 
DVTs (56%) were distal, suggesting a risk of over-
diagnosis and overtreatment [26]. Table 3 offers a 
comparison of the results obtained with the simpli-
fied or complete lower-limb venous CUS.
Ascending Phlebography
Ascending phlebography is still considered the diag-
nostic standard for diagnosing DVT but it is invasive, 
costly, and not devoid of risk. It consists in the injec-
tion of iodinated contrast dye in a superficial foot 
vein with sequential radiograms of the leg in order to 
follow the dynamic course of the contrast in the veins. 
Tourniquets can be used to force the dye into the 
deep veins but their use is controversial. The docu-
mentation is adequate when images are obtained in 
different views, and a filling defect surrounded by 
contrast is characteristic of a fresh thrombus.
Sequential Diagnostic Strategies for 
Suspected DVT
Several noninvasive strategies have been reported to 
have a high sensitivity for diagnosing DVT [3]. Some 
rely on serial proximal CUS of proximal veins (com-
mon femoral, superficial femoral, and popliteal veins). 
The rationale for repeating CUS after 1 week in pa-
tients in whom it was initially negative is the detection 
of the rare proximal extension of the distal DVTs that 
were not searched for. Since the yield of repeat CUS 
after 1 week is very low [14, 21, 22], CUS has been 
combined with a clinical prediction rule and/or DD 
measurement to lower the number of necessary repeat 
compression sonograms [14, 21, 22, 28, 29]. In another 
strategy, single CUS was restricted to patients with a 
DD concentration above a critical cutoff level (500 µg/
l), thereby avoiding about 30% of CUS exams [13]. All 
these strategies are associated with a low (about 2% or 
less) 3-month thromboembolic risk, which is similar to 
that observed in suspected patients left untreated fol-
lowing a normal phlebogram [30]. In a randomized 
study, Wells et al. compared the clinical outcome in 
530 patients who underwent CUS (control group) and 
566 patients who underwent DD testing followed by 
CUS unless the DD test was negative and the patient 
was considered at low clinical probability [31]. The 
3-month thromboembolic risk among patients in 
whom the initial diagnostic strategy had ruled out 
DVT was 0.4% in the DD group, compared with 1.4% 
in the control group. The difference did not reach sta-
tistical significance but the use of DD resulted in a 
highly significant reduction in the use of CUS, since 
39% of patients did not require ultrasound imaging. 
Overall, modern diagnostic approach to DVT is based 
upon evaluation of clinical probability, DD measure-
ment and CUS. Figure 1 suggests a possible diagnostic 
algorithm for suspected DVT and the interested read-
er may find a complete description of all diagnostic 
strategies used in the literature in a recent review [32].
Treatment of Deep Vein Thrombosis
Medical Treatment
The aims of treatment are to relieve symptoms, re-
duce the risk of PE, and prevent postthrombotic syn-
drome (PTS) and recurrent VTE. Anticoagulation is 
Table 3. Comparison of diagnostic strategies including proximal only or proximal and distal compression ultrasonography 
(CUS) for diagnosing deep vein thrombosis (DVT; outcome studies).
Tabelle 3. Vergleich verschiedener diagnostischen Strategien mit ausschließlich proximaler oder kompletter (proximaler + 
distaler) Kompressionsultrasonographie (CUS) für die Diagnose der tiefen Venenthrombose (DVT; pragmatische Studien).
Series Patients  Prevalence  Proportion Number of CUS 3-month thrombo-
 (n)  of DVT (%) of distal  performed per embolic risk 
   DVT (%) 100 patients (n) [% (95% CI)]a
Proximal CUS only
Cogo et al. [21] 1,702 24 – 176 0.7 (0.3–1.2)
Bernardi et al. [22]    946 28 – 109 0.4 (0–0.9)
Wells et al. [14]    593 16 – 128 0.6 (0.1–1.8)
Perrier et al. [13]    474 24 –   73 2.6 (0.2–4.9)
Kraaijenhagen et al. [24] 1,756 22 – 121 0.6 (0.1–1.6)
Proximal and distal CUS
Elias et al. [25]    623 36 45 100 0.5 (0.1–1.8)
Schellong et al. [26] 1,646 17 56 100 0.3 (0.1–0.8)
Stevens et al. [27]    445 14 31 100 0.8 (0.2–2.3)
a during 3-month follow-up in patients left untreated
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VTE because UFH is much less expensive than 
LMWH, at least in some countries.
Thrombolysis and Invasive Treatment
Systematically administered or catheter-directed 
thrombolysis should not be routinely used in patients 
with lower-limb DVT and should be confined to pa-
tients requiring limb salvage (phlegmasia coerulea 
dolens). Catheter extraction, fragmentation or surgi-
cal thrombectomy should not be used in routine for 
the treatment of DVT [37]. However, these options 
may be discussed in young patients with massive iso-
lated iliofemoral DVT at risk of limb gangrene secon-
dary to massive, proximal venous occlusion.
Duration and Intensity of Anticoagulant 
Long-Term Treatment
The duration of anticoagulant treatment following a 
venous thromboembolic episode has always been a 
matter of debate with recommended durations fol-
lowing a first episode varying between 3 months and 
1 year, depending upon the weight given to the re-
spective risks of recurrence and bleeding induced by 
the treatment [38]. Since VTE is a recurrent disease, 
anticoagulation should ideally last forever. However, 
the risk of recurrence diminishes with time and the 
risk of bleeding, after an initial peak, is rather con-
stant over time. Thus, there must be some time point 
the mainstay of treatment of DVT. The initial treat-
ment of acute DVT is based upon administration of 
LMWH or unfractionated heparin (UFH).
The Seventh ACCP (American College of Chest 
Physicians) Consensus on Antithrombotic and 
Thrombolytic Therapy recommends treating patients 
with a high clinical probability of DVT while awaiting 
the results of diagnostic tests (grade 1C+). However, 
as the prevalence of DVT in patients with an interme-
diate clinical probability of DVT may be as high as 
20–30%, a more appropriate option would be to be-
gin anticoagulation while awaiting outcome of diag-
nostic tests also in patients with an intermediate clini-
cal probability of DVT. In most cases, warfarin can 
be started on the 1st day. LMWH or UFH should be 
continued for at least 5 days and until the Interna-
tional Normalized Ratio (INR) is within the thera-
peutic range (i.e., between 2 and 3) on at least two 
dosages at an interval of 24 h.
LMWH has become the standard of care for the 
initial treatment of DVT as it is as effective and safe 
as UFH but is more practical to use and has a more 
favorable side effects’ profile. Many available LMWHs 
may be used once or twice daily. Contrarily to UFH, 
laboratory monitoring is not mandatory in the vast 
majority of patients treated with LMWHs. Some ex-
ceptions are patients with renal impairment, obesity 
and pregnancy. As LMWHs are excreted by the kid-
ney, they should not be used in patients with a creati-
nine clearance of < 30 ml/min. In these patients using 
UFH is recommended.
The predictable anticoagulant response of 
LMWHs allows out-of-hospital treatment in more 
than 80% of patients with acute DVT. Outpatient 
therapy offers reduced economic costs to patients 
and the health-care system as a result of decreased 
resource utilization. Once or twice daily dosing and 
fixed dosages combined with a well-planned program 
of patient education and professional support offer 
convenience to patients while enhancing successful 
adherence to home treatment. In 1996, the results of 
a meta-analysis of 20 randomized controlled studies 
comparing multiple clinical outcomes of LMWH and 
UFH [33] showed that treatment with LMWH had a 
more favorable benefit-to-risk ratio than treatment 
with UFH. More recently, two other meta-analyses 
showed that treatment with LMWH is at least as ef-
fective as UFH in terms of risk of major bleeding, PE, 
and recurrent DVT [34, 35]. The safety and efficacy 
profiles of LMWHs, such as dalteparin, enoxaparin, 
nadroparin, logiparin and tinzaparin, are well estab-
lished. Recently, Kearon et al. demonstrated that 
fixed-dose weight-adjusted subcutaneous UFH was 
as effective and safe as LMWH in patients with acute 
VTE and was suitable for outpatient treatment [36], a 
finding that might impact the management of acute 
 
Negative
No treatment
No DVT
No treatment
DVT
Treatment
Positive
CUS
Sensitive or less sensitive
DD
Low
Negative
No treatment
No DVT
No treatment
DVT
Treatment
Positive
CUS
Sensitive
DD
Intermediate
No DVT
Phlebography
DVT
Treatment
CUS
No DD
High
Assessment of clinical probability
Suspicion of DVT
Figure 1. Diagnostic algorithm for clinically suspected deep vein thrombosis (DVT). 
Sensitive D-dimer assay means at least 95% sensitivity for the presence of DVT.
CUS: lower limb venous compression ultrasonography; DD: D-dimer measure-
ment.
Abbildung 1. Diagnostischer Algorithmus bei klinischem Verdacht auf tiefe Ve-
nenthrombose (DVT). Ein sensitiver D-Dimer-Test bedeutet eine Sensitivität von 
mindestens 95% für die Anwesenheit einer DVT.
CUS: venöse Kompressionsultrasonographie; DD: D-Dimer-Bestimmung.
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for which the bleeding risk exceeds the protective ef-
fect of the treatment, which should then be stopped 
[37].
As already mentioned, there is no consensus for 
duration of anticoagulation for all situations clini-
cians may be faced with. In practice, after an initial 
course of 3–12 months of conventional-intensity war-
farin, the prolongation of anticoagulation treatment 
may be tailored on an individual basis. Some indica-
tions for long-term anticoagulation are active neopla-
sia, antiphospholipid syndrome with previous VTE 
and persistent antiphospholipid antibodies, and some 
congenital thrombophilias as severe antithrombin or 
protein C deficiency [37]. Maintaining long-term an-
ticoagulation may be discussed as well in presence of 
two or more previous idiopathic VTEs, even if the 
evidence supporting this attitude are scarce. Obvi-
ously, the necessity of maintaining long-term antico-
agulation should be reassessed annually, in particular 
to weight the possibility of new clinical events associ-
ated with an increased hemorrhagic risk, which could 
limit the benefit-risk ratio of long-term anticoagulant 
treatment. The option of prolonging the treatment 
with low-intensity warfarin (for example INR be-
tween 1.5–2) may be useful at least in selected pa-
tients at higher risk of bleeding [39, 40]. A shorter 
period of anticoagulation (3 months) is accepted for 
VTE occurring after a transient risk factor like sur-
gery or trauma [37].
Compression Treatment of DVT in the Acute 
and Chronic Phases
The PTS develops in 20–50% of patients after symp-
tomatic DVT and is the most common long-term 
complication of DVT [41–43]. Patients with PTS ex-
perience pain, heaviness, swelling, cramps, itching 
or tingling in the affected limb. Symptoms may be 
present in various combinations and may be persis-
tent or intermittent. Symptoms are usually aggra-
vated by standing or walking and improve with rest-
ing, leg elevation any lying down. In severe cases, 
skin changes and ulcers may develop. The frequency 
of PTS is likely to be reduced by preventing DVT 
with the use of effective thromboprophylaxis in 
high-risk patients and settings. However, once DVT 
has developed, the use of compression stockings for 
2 years after DVT appears to reduce the incidence 
and severity of PTS.
To date, three trials have evaluated the effec-
tiveness of long-term use of elastic stockings for the 
prevention of PTS after acute DVT. The first study 
by Brandjes et al. randomly allocated 194 patients to 
daily use of a 30- to 40-mmHg knee-length elastic 
compression stockings for at least 2 years or no 
stockings [44]. Use of elastic compression stockings 
resulted in a decrease from 47% to 20% of mild/
moderate PTS and a decrease from 23% to 11% of 
severe PTS. A second study by Ginsberg et al. com-
pared the effect of active stockings to sham stock-
ings to prevent PTS after proximal DVT in patients 
who had venous valvular incompetence but no clini-
cal PTS 1 year after the index event [45]. This study 
showed no benefit of elastic stockings as none (0%) 
of the 24 patients allocated to the active stockings 
developed PTS, compared with one (4.4%) of 23 pa-
tients treated with sham stockings (p = 0.49). An-
other trial by Prandoni et al. evaluated the effective-
ness of 30- to 40-mmHg elastic stockings versus no 
stockings in 180 patients after a first symptomatic 
proximal DVT [46]. The 2-year cumulative inci-
dence of PTS, evaluated by using the Villalta’s score 
was 25% in the stocking group compared with 49% 
in the control group (p = 0.011). Lastly, a meta-ana-
lysis pooled these three studies and reported an 
overall 54% relative risk reduction in PTS with the 
use of stockings [47]. Even if the lack of blinding in 
the two positive studies reduces the confidence in 
the results as scores used for the evaluation of PTS 
are highly subjective and even if some questions 
such as the optimal length and strength of compres-
sion remain unanswered, initiation of compression 
therapy has to be considered an important point in 
the care of acute DVT [48].
Treatment of Calf DVT
In spite of the reassuring data obtained from the out-
come studies using proximal CUS (Table 3), recent 
consensus conferences, including that of the ACCP, 
still recommend to treat calf DVT with anticoagu-
lants for a period of 3 months [37]. Nevertheless, opt-
ing for a 3-month anticoagulant treatment in the 
presence of a distal DVT raises several problems. 
First, series based on serial ultrasonography indicate 
that only a small fraction of distal DVTs extends 
proximally in medical outpatients. Indeed, the rate of 
proximal DVTs detected by the repeated ultrasound 
varies from 0.9% to 5.7% [14, 21, 22, 24]. Second, the 
randomized DOTAVK study showed a similar safety 
of an anticoagulant treatment of 6 or 12 weeks for 
distal DVT, suggesting that a shorter period of anti-
coagulation (6 weeks) would be safe [49]. Third, mus-
cle vein thromboses (i.e., gemellar and soleal vein 
thrombosis) are probably less dangerous than throm-
bosis of the deep distal veins (i.e., peroneal and tibial 
posterior veins). Macdonald et al. showed, in a pro-
spective study where muscular thromboses were not 
treated but followed by ultrasonography, that only 
3% of muscular thromboses extended in the popliteal 
vein [50]. This suggests that the vast majority of mus-
cular vein thromboses need either no anticoagulation 
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or a shorter period of anticoagulation. Fourth, in 
studies using proximal and distal CUS, half of detect-
ed thromboses were distal (Table 3) and a risk of 
overtreatment should not be neglected. Therefore, 
the 1A grade of recommendation delivered by the 
ACCP consensus conference suggesting a similar 
treatment for proximal DVTs and calf DVTs [37] 
seems not to be supported by the available evidence.
Conclusion and Perspectives
Venous thromboembolic disease encompasses a wide 
spectrum of conditions with various severity and prog-
nostic implications. DVT is an important cause of mor-
bidity and mortality, and as the awareness of this pa-
thology has increased during the last 2 decades, the 
prevalence of the disease in suspected populations has 
dramatically decreased. Recent studies have shown 
that algorithms combining simple diagnostic tests may 
provide a safe diagnostic approach to suspected DVT, 
with a 3-month thromboembolic risk similar to or low-
er than that reported after a normal phlebography, the 
accepted gold standard. Assessment of clinical proba-
bility, done empirically or by a prediction rule, has 
shown to be highly useful and allows identifying pa-
tients with a low prevalence of the disease, who can be 
investigated by noninvasive diagnostic tools. Plasma 
DD measurements have been widely validated and al-
low to rule out the disease with an acceptable safety in 
selected patients. CUS has become the cornerstone 
diagnostic test for DVT and its diagnostic performanc-
es are excellent in the case of symptomatic proximal 
DVTs. Many algorithms combining in various order 
these last three tests have been validated, and may be 
safely used in clinical practice. In spite of these advanc-
es, the field faces several challenges for the future. One 
challenge will consist in establishing which conditions 
need to be treated with anticoagulant drugs, a question 
that pertains essentially to calf or muscle vein throm-
bosis. Its answer will have consequences for diagnostic 
algorithms.
As a matter of fact, LMWHs have considerably 
simplified the initial management of DVT and al-
lowed out-of-hospital treatment. However, their por-
cine origin is still a concern. Several new, totally syn-
thetic, orally active anticoagulant compounds, such 
as direct thrombin or factor Xa inhibitors, are pres-
ently being tested in clinical studies and could pro-
foundly modify DVT treatment in the near future.
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